ClinicalTrials.gg
RecruitingNCT05906576Updated Sep 30, 2026

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

A Phase 4 interventional study of Infliximab in Crohn Disease, sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing infliximab in Crohn Disease — 10 open to participants now, 11 under way, 1 of them phase 3. Infliximab · Crohn Disease.

Planned enrollment
32nd of 41
30 · median 100
Started
2023
with 3 others
Phase 4
21 of 42
6 open now
Primary completion
2026-11
later than 6 of 10 live
Registered
38th of 42
by date

Among the 42 studies testing infliximab in Crohn Disease, this one is the 32nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 38th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 42 studies testing infliximab in Crohn Disease are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing infliximab in Crohn Disease, or all of them as a file.
02

Study summary

Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.

Read the detailed description

This is a prospective, multicenter registry study in Chinese pediatric Crohn's disease patients. A total of 30 subjects were planned to be enrolled and treated with Infliximab. Subjects were observed for 102 weeks after administration to evaluate the clinical efficacy and safety of infliximab in the treatment of children with Crohn's disease in a real diagnostic setting.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ranged 6 to 17 years (both inclusive), no gender limitation.
  2. A clear diagnosis was made in children with moderate to severe active stage (PCDAI≥30) Crohn's disease refer to the expert consensus on the diagnosis and treatment of inflammatory bowel disease in children (2019 edition).
  3. Patients and/or their guardians must sign ICF, and the research agreement/ICF for data collection and data verification shall comply with local laws and regulations.
  4. The patient received infliximab for the first time.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to infliximab use (such as severe infection, active tuberculosis, lymphoma or other ), moderate to severe heart failure, and allergies to other murine proteins, infliximab or any component of this product.
  2. Those who accept other anti-TNF-α any biological drugs or any other biologicals.
  3. Patients who plan to receive within 3 months before signing the or during the treatment period
  4. Those who have been or being enrolled in other clinical studies within 3 months prior to signing ICF
  5. The investigator judges the subject inappropriate to be included in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Infliximab

    Infliximab for the treatment of Crohn's disease in children

    Drug: Infliximab

Interventions

  • Infliximab in the treatment of Crohn's disease in children

    Also known as: CMAB008

06

What researchers measure

Primary outcomes

  1. Clinical response rate at 14 weeks

    Clinical response: PCDAI decreased ≥15 points and total PCDAI≤ 30 points

    Time frame: up to 14 weeks

Secondary outcomes

  1. Clinical remission rate at week 14 and 54

    Clinical remission: PCDAI≤10

    Time frame: up to 54 weeks

  2. Endoscopic response rate at week 14 and 54

    Endoscopic response: SES-CD decreased ≥ 50%

    Time frame: up to 54 weeks

  3. Mucosal healing rate at week 14 and 54

    Mucosal healing: SES-CD 0-2

    Time frame: up to 54 weeks

  4. Changes from baseline in height-for-age z-score (HAZ), weight-for-age z-score (WAZ) and BMI-for-age z-score at week 14 and 54

    The z-score is converted from anthropometric measurements based on the World Health Organization growth reference. The z-score including: height-for-age z-score (HAZ), weight-for-age z-score (WAZ) and BMI-for-age z-score.

    Time frame: up to 54 weeks

  5. Changes from baseline in serum C-reactive protein at week 14 and 54

    Changes from baseline in serum C-reactive protein at week 14 and 54

    Time frame: up to 54 weeks

  6. Changes from baseline in erythrocyte sedimentation rate at week 14 and 54

    Changes from baseline in erythrocyte sedimentation rate at week 14 and 54

    Time frame: up to 54 weeks

  7. Changes from baseline in the rate of delayed development of adolescents at 14 and 54 weeks

    Delayed development: Female children over 13 years old and male children over 14 years old are in the Tanner stage I

    Time frame: up to 54 weeks

  8. ADA positive rate

    ADA positive rate at week 14 and 54

    Time frame: up to 54 weeks

  9. Percentage of participants with Adverse Events

    Total Frequency of Adverse Events/Serious Adverse Events Within the Whole Time of the Study

    Time frame: up to 102 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 18, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and index terms
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05906576
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Sep 21, 2023
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Wu Jie
Contact
licli2860@sina.com
18940251108
Wu Jie
principal investigator · Beijing Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion